Jakub Rzeszótko

Mr. Jakub Rzeszótko

University of Wrocław

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KJKarolina Jendryczko
Karolina Jendryczko
JCJulia Chudzian
Julia Chudzian
NSNatalia Skinder
Natalia Skinder
ŁOŁukasz Opaliński
Łukasz Opaliński
JRJakub Rzeszótko
Jakub Rzeszótko
ASAnna Szlachcic
Anna Szlachcic
Fibroblast growth factor receptors (FGFRs) are emerging targets for directed cancer therapy. Presented here is a new FGFR1-targeting conjugate, the peptibodyF2, which employs peptibody, a fusion of peptide and the Fc fragment of human IgG as a selective targeting agent and drug carrier. Short peptide based on FGF2 sequence was used to construct a FGFR1-targeting peptibody. We have shown that this peptide ensures specific delivery of peptibodyF2 into FGFR1-expressing cells. In order to use peptibodyF2 as a delivery vehicle for cytotoxic drugs, we have conjugated it with MMAE, a drug widely used in antibody–drug conjugates for targeted therapy. Resulting conjugate shows high and specific cytotoxicity towards FGFR1-positive cells, i.e., squamous cell lung carcinoma NCI-H520, while remaining non-toxic for FGFR1-negative cells. Such peptibody–drug conjugate can serve as a basis for development of therapy for tumors with overexpressed or malfunctioning FGFRs.